

1 **Elevated plasma levels of CXCL16 in severe COVID-19 patients**

2  
3 Sandra P. Smieszek<sup>1</sup>, Vasilios M. Polymeropoulos<sup>1</sup>, Christos M. Polymeropoulos<sup>1</sup>, Bartłomiej P.  
4 Przychodzen<sup>1</sup>, Gunther Birznieks<sup>1</sup>, Mihael H. Polymeropoulos<sup>1</sup>

5

6

7 <sup>1</sup> Vanda Pharmaceuticals Inc., Washington, DC, USA

8

9 **Corresponding author**

10 [sandra.smieszek@vandapharma.com](mailto:sandra.smieszek@vandapharma.com)

11

12 **Declarations:**

13 Funding: no relevant funding

14

15 Conflicts of interest/Competing interests (include appropriate disclosures): authors are  
16 employees of Vanda Pharmaceuticals Inc.

17

18 Availability of data and material (data transparency): Data available upon request

19

20 Code availability (software application or custom code): not applicable

21

22 Authors' contributions (optional: please review the submission guidelines from the journal  
23 whether statements are mandatory): not applicable

24

25 Additional declarations for articles in life science journals that report the results of studies  
26 involving humans and/or animals: not applicable

27

28 Ethics approval (include appropriate approvals or waivers): Advarra IRB; Pro00043096

29

30 Consent to participate (include appropriate statements): All participants were consented prior to  
31 participation

32

33 Consent for publication (include appropriate statements): not applicable

34

35

36

37

38  
39

## 40 **Abstract**

41 Genome-wide association studies have recently identified 3p21.31, with lead variant pointing to  
42 the *CXCR6* gene, as the strongest thus far reported susceptibility risk locus for severe  
43 manifestation of COVID-19. In order to determine its role, we measured plasma levels of  
44 Chemokine (C-X-C motif) ligand 16 (CXCL16) in the plasma of COVID-19 hospitalized  
45 patients. CXCL16 interacts with CXCR6 promoting chemotaxis or cell adhesion. The  
46 CXCR6/CXCL16 axis mediates homing of T cells to the lungs in disease and hyper-expression is  
47 associated with localised cellular injury. To characterize the CXCR6/CXCL16 axis in the  
48 pathogenesis of severe COVID-19, plasma concentrations of CXCL16 collected at baseline from  
49 115 hospitalized COVID-19 patients participating in ODYSSEY COVID-19 clinical trial were  
50 assessed together with a set of controls. We report elevated levels of CXCL16 in a cohort of  
51 COVID-19 hospitalized patients. Specifically, we report significant elevation of CXCL16 plasma  
52 levels in association with severity of COVID-19 (as defined by WHO scale) ( $P$ -value<0.02). Our  
53 current study is the largest thus far study reporting CXCL16 levels in COVID-19 hospitalized  
54 patients (with whole-genome sequencing data available). The results further support the  
55 significant role of the CXCR6/CXCL16 axis in the immunopathogenesis of severe COVID-19  
56 and warrants further studies to understand which patients would benefit most from targeted  
57 treatments.

58

## 59 **Introduction**

60

61 Genome-wide association studies have recently identified 3p21.31, encompassing the *CXCR6*  
62 gene, as the strongest thus far reported susceptibility region associated with a severe  
63 manifestation of COVID-19 (rs73064425, OR=2.14,  $P$ -value=4.77E-30)<sup>1</sup>. Another lead severity  
64 variant rs10490770:T>C pointing to *CXCR6* was also reported with a  $P$ -value of 1.443E-73  
65 (hospitalization) and 2.20E-61 (critical illness) by the COVID-19 Host Genetics Initiative<sup>2</sup>.  
66 Nakanishi et al., reported that risk allele (rs10490770) carriers experienced an increased risk of  
67 COVID-19 related mortality (HR 1.5, 95% CI 1.3-1.8)<sup>3</sup>. Risk allele carriers had increased odds  
68 of several COVID-19 complications: severe respiratory failure (OR 2.0, 95% CI 1.6-2.6), venous  
69 thromboembolism (OR 1.7, 95% CI 1.2-2.4)<sup>3</sup>.

70 Chemokine (C-X-C motif) ligand 16 (CXCL16) is synthesized as a transmembrane molecule  
71 that is expressed as a cell surface-bound molecule, and as a soluble chemokine<sup>4</sup>. CXCL16  
72 interacts with CXCR6 in leukocytes and other cells promoting chemotaxis or cell adhesion. It  
73 has been shown that inflammatory cytokines such as IFN $\gamma$  and TNF $\alpha$  promote CXCL16  
74 expression<sup>5</sup>. CXCL16 has been previously implicated in the pathogenesis of lung injury upon  
75 which it is released and functions as a chemoattractant for CXCR6+ T, natural killer (NK), B,  
76 and dendritic cells<sup>6</sup>. CXCL16 levels were elevated in the serum of acute lung injury patients in  
77 comparison to controls<sup>6</sup>. CXCR6 is expressed on T cells not only in T helper type 1 (Th1)  
78 inflammation but also in Th2 inflammation, where it is increased after allergen challenge. It was  
79 previously shown that reduction in CD8+ T-lymphocytes occurred between C57BL/6 and  
80 CXCR6KO mice<sup>7</sup>. CXCR6 is a major coreceptor of HIV type 2 variants<sup>8</sup>. The CXCR6/CXCL16  
81 axis mediates homing of T cells to the lungs in disease and when hyper expressed is associated  
82 with localized cellular injury<sup>7</sup>. This CXCR6/CXCL16 axis is involved in lung pathology also  
83 associated with other infections, including influenza. Antagonism was reported to result in  
84 reduced inflammation<sup>6</sup>. In a recent report authors have shown that knockdown of CXCR6  
85 reversed the effect of CXCL16 and so did the treatment with the p38 inhibitor SB203580  
86 abolished the effects of CXCL16<sup>6</sup>. Another recent study has shown that the absence of CXCR6  
87 significantly decreases airway CD8 resident memory T cells due to altered trafficking of  
88 CXCR6<sup>-/-</sup> cells within  
89 the lung<sup>9</sup>, Moreover mice lacking CXCL16 also had decreased CD8 resident memory T cells in  
90 the airways and ultimately blocking CXCL16 resulted in the inhibition of the steady-state  
91 maintenance of airway resident memory T cells<sup>9</sup>.

92

93 **Methods**

94 ***Participants***

95 ODYSSEY is a double-blinded Phase 3 study with a planned randomization of a total of 300  
96 hospitalized severely ill COVID-19 patients (Clinicaltrials.gov: NCT04326426). Inclusion  
97 criteria for the study comprised of: 1. Adults aged 18-90; 2. confirmed laboratory COVID-19  
98 infection; 3. confirmed pneumonia by chest radiograph or computed tomography; 4. fever  
99 defined as temperature  $\geq 36.6$  °C armpit,  $\geq 37.2$  C oral, or  $\geq 37.8$  °C rectal since admission or the  
100 use of antipyretics; 5.  $\text{PaO}_2 / \text{FiO}_2 \leq 300$ ; 6. In patient hospitalization. Patients were to be  
101 followed for up to 28 days to record clinical outcomes. Patients' clinical progress was recorded  
102 on a 7 point clinical status ordinal scale defined as follows: 1- Death; 2- Hospitalized on  
103 mechanical ventilation or ECMO; 3- Hospitalized on non invasive ventilation or high-flow  
104 oxygen supplementation; 4- Hospitalized requiring supplemental oxygen; 5- Hospitalized not  
105 requiring supplemental oxygen, requiring continued medical care; 6- Hospitalized not requiring  
106 supplemental oxygen, not requiring continued medical care; 7- Not hospitalized. Main Exclusion  
107 Criteria included: 1. Inability to provide informed consent or to have an authorized relative or  
108 designated person provide informed consent, or to comply with the protocol requirements; 2.  
109 Known allergy to tradipitant or other neurokinin-1 antagonists; 3. Pregnancy; 4. Uncontrolled  
110 HIV, HBV, or HCV infection; 5. Other uncontrolled medically significant diseases; 6.  
111 Enrollment in another clinical trial of an investigational therapy; 7. Alanine aminotransferase  $>$   
112 5X Upper Limit of Normal or Creatinine clearance  $< 50$  m 174 l / min; 8. Requiring mechanical  
113 ventilation for  $> 72$  hours.

114

115 ***CXCL16 measurement***

116 To characterize the CXCR6/CXCL16 axis in the pathogenesis of severe COVID-19, plasma  
117 concentrations of CXCL16 from 115 hospitalized COVID-19 patients participating in  
118 ODYSSEY COVID-19 clinical trial ((NCT04326426)) and additionally samples from 37  
119 controls were assessed. CXCL16 levels in plasma were determined with an enzyme-linked  
120 immunosorbent assay (ELISA) assay (Thermofisher ID: # EHCXCL16) performed on plasma  
121 collected at baseline in cases and in a set of healthy controls (assay range 2.74-2000 pg/mL).

122

### 123 *Genetic Analysis*

124

125 Incoming nucleic acid samples are quantified using fluorescent-based assays (PicoGreen) to  
126 accurately determine whether sufficient material is available for library preparation and  
127 sequencing. DNA sample size distributions are profiled by a Fragment Analyzer (Advanced  
128 Analytics) or BioAnalyzer (Agilent Technologies), to assess sample quality and integrity.  
129 HumanCoreExome 24v1.3 array was performed on all human DNA samples sequenced. Whole  
130 genome sequencing (WGS) libraries were prepared using the Truseq DNA PCR-free Library  
131 Preparation Kit. Whole Genome data were processed on NYGC automated pipeline. Paired-end  
132 150 bp reads were aligned to the GRCh37 human reference (BWA-MEM v0.7.8) and processed  
133 with GATK best-practices workflow (GATK v3.4.0). The mean coverage was 35.8, it reflects the  
134 samples average. All high quality variants obtained from GATK were annotated for functional  
135 effects (intronic, intergenic, splicing, nonsynonymous, stopgain and frameshifts) based on  
136 RefSeq transcripts using Annovar<sup>31</sup>. Additionally, Annovar was used to match general  
137 population frequencies from public databases (Exac, gnomAD, ESP6500, 1000g) and to

138 prioritize rare, loss-of-function variants. Linear models adjusted for PC, age and sex were  
139 conducted in PLINK.

140

141

142

143

144

145

146

## 147 **Results**

148 We report elevated levels of CXCL16 in a set of COVID-19 hospitalized patients. Baseline  
149 demographics of the studied cohort are presented in **Table 1**. Clinical characteristics are provided  
150 in **Table 2**. Specifically, we report significantly elevated levels of CXCL16 in a subset of  
151 COVID-19 severe (as defined by WHO scale) hospitalized patients ( $P$ -value $<0.02$ ) displayed on  
152 **Figure 1**). The most significant difference reported in plasma CXCL16 between most severe  
153 (WHO- 2) COVID-19 hospitalized cases and less severe patients ( $P$ -value $<0.02$ ) as well as most  
154 severe and controls. We furthermore report a larger variance within the cases, signifying further  
155 necessity of stratification based on clinical characteristics (ANCOVA  $p$ -value – 0.001,  
156 covariates: age, sex, BMI). The effect is not driven by age nor BMI, or sex (Figure 2 –  
157 Supplemental Material). We further investigated the correlation between IFN- $\gamma$ , TNF- $\alpha$ . We  
158 report lack thereof at baseline (Figure 3 – Supplemental Material). We were able to replicate the  
159 lead variant association (rs10490770) in our cohort of hospitalized patients (cases n 140 control n

160 1900) with confirmed COVID-19 infection (OR 1.9, CI 1.2-3.5,  $P$ -value  $<0.002$ ). The carriers of  
161 this variant were at higher risk, of being in the hospitalized severe group (as defined by the WHO  
162 scale), finding which is consistent across multiple COVID-19 GWAS results reported thus far.  
163 Moreover, we inspected the association between the lead variant status and directly CXCL16  
164 plasma levels. This association between lead coding variant carrier status and CXCL16 levels did  
165 not attain statistical significance (result that is trending), a finding that warrants further  
166 replication in a larger sample size. FYCO1 variant within the extended haplotype did attain  
167 statistical significance ( $P$ -value  $<0.0001$ ) and the result is displayed in Supplementary Figure 4.

## 168 **Discussion**

169 Previously it was demonstrated that circulating CD8+CXCR6+ T cells were significantly  
170 elevated with advanced age, yet virtually absent in patients with severe COVID-19. In a smaller  
171 sample set, plasma levels of CXCL16 were significantly upregulated in severe COVID-19  
172 patients compared to mild COVID-19 patients<sup>10</sup>. Differential expression of *CXCR6* and *CXCL16*  
173 mRNA was observed in severe COVID-19 compared to mild disease and significant functional  
174 polymorphisms in *CXCR6* are linked to viral control<sup>1</sup>.

175 Furthermore, based on lung tissue autopsy data, the top differentially expressed genes from  
176 GWAS hits included *FYCO1*, specifically in AT2 cells, ciliated cells, and club cells<sup>11</sup>. *FYCO1*  
177 coding variant (rs33910087) is an eQTL for *CXCR6*, whereas *CXCR6* was differentially  
178 expressed in lung CD8 T cells in COVID-19 infected lung tissue<sup>11</sup>.

179

180

181 Prior studies targeting the axis (both knockout and pharmacological blocking) support the  
182 hypothesis that antagonism may constitute potential therapies<sup>6,9</sup>. It may be the case that the  
183 treatment of the hyper-expression of the CXCL16/CXCR6 axis hence reduction of the severely  
184 heightened homing signal may elicit such therapeutic effects, for example in a cytokine storm.  
185 Besides the potential implications in lung injury, both the CXCR6 and its ligand plays an  
186 important role in mediating a proinflammatory microenvironment for tumor growth in  
187 hepatocellular carcinoma<sup>12</sup>. Here targeting the CXCR6/CXCL16 axis is needed to elucidate the  
188 mechanism whereby neutrophils are affected in the tumor environment<sup>12</sup>. Authors propose one  
189 such orally bioavailable compound - antagonist of the CXCR6 receptor shown to decrease  
190 growth in a mouse xenograft model of hepatocellular carcinoma<sup>12</sup>. Further studies on antagonism  
191 of the axis are needed to explain the timing of such antagonism treatment that would result in  
192 optimal outcomes. Our current study, is the largest thus far reporting on the plasma levels of  
193 CXCL16 in association with severity in COVID-19 patients. The results support the significant  
194 role of the CXCR6/CXCL16 axis in the immunopathogenesis of severe COVID-19. Further  
195 studies warrant analysis of outcomes based on the carrier status for this locus and on the levels of  
196 CXCL16.

197

198

199

200

201

202



203

204

205

206 References

207

- 208 1. Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in Covid-19.  
209 *medRxiv*. 2020;17(8):25. <https://doi.org/10.1101/2020.09.24.20200048>.
- 210 2. Initiative C-19 HG. Mapping the human genetic architecture of COVID-19. *Nature*. 2021.  
211 doi:10.1038/s41586-021-03767-x
- 212 3. Nakanishi T, Pigazzini S, Degenhardt F, et al. Age-dependent impact of the major common genetic  
213 risk factor for COVID-19 on severity and mortality. *medRxiv*. 2021.  
214 doi:10.1101/2021.03.07.21252875
- 215 4. Collado A, Marques P, Escudero P, et al. Functional role of endothelial CXCL16/CXCR6-platelet-  
216 leucocyte axis in angiotensin II-associated metabolic disorders. *Cardiovascular Research*.  
217 2018;114(13):1764-1775. doi:10.1093/cvr/cvy135
- 218 5. Abel S, Hundhausen C, Mentlein R, et al. The Transmembrane CXC-Chemokine Ligand 16 Is  
219 Induced by IFN- $\gamma$  and TNF- $\alpha$  and Shed by the Activity of the Disintegrin-Like Metalloproteinase  
220 ADAM10. *The Journal of Immunology*. 2004;172(10):6362 LP-6372.  
221 doi:10.4049/jimmunol.172.10.6362
- 222 6. Tu G-W, Ju M-J, Zheng Y-J, et al. CXCL16/CXCR6 is involved in LPS-induced acute lung injury via  
223 P38 signalling. *Journal of cellular and molecular medicine*. 2019;23(8):5380-5389.  
224 doi:10.1111/jcmm.14419
- 225 7. Ashhurst AS, Flórido M, Lin LCW, et al. CXCR6-Deficiency Improves the Control of Pulmonary  
226 Mycobacterium tuberculosis and Influenza Infection Independent of T-Lymphocyte Recruitment  
227 to the Lungs. *Frontiers in Immunology*. 2019;10:339. doi:10.3389/fimmu.2019.00339
- 228 8. Blaak H, Boers PHM, Gruters RA, Schuitemaker H, van der Ende ME, Osterhaus ADME. CCR5,  
229 GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants  
230 isolated from individuals with and without plasma viremia. *Journal of virology*. 2005;79(3):1686-  
231 1700. doi:10.1128/JVI.79.3.1686-1700.2005
- 232 9. Wein AN, McMaster SR, Takamura S, et al. CXCR6 regulates localization of tissue-resident  
233 memory CD8 T cells to the airways. *Journal of Experimental Medicine*. 2019;216(12):2748-2762.  
234 doi:10.1084/jem.20181308
- 235 10. Payne DJ, Dalal S, Leach R, et al. The CXCR6/CXCL16 axis links inflamm-aging to disease severity in  
236 COVID-19 patients. *bioRxiv*. January 2021:2021.01.25.428125. doi:10.1101/2021.01.25.428125
- 237 11. Delorey TM, Ziegler CGK, Heimberg G, et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology  
238 and cellular targets. *Nature*. 2021;595(7865):107-113. doi:10.1038/s41586-021-03570-8

239 12. Peddibhotla S, Hershberger PM, Jason Kirby R, et al. Discovery of small molecule antagonists of  
240 chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model  
241 of hepatocellular carcinoma. *Bioorganic & medicinal chemistry letters*. 2020;30(4):126899.  
242 doi:10.1016/j.bmcl.2019.126899

243

244

245

246

247

248

249


250

251

252


253

254 **Figure 1** Baseline plasma CXCL16 levels in association with severity of COVID-19 manifestation and case  
255 control analysis. Severe (as defined by WHO scale) cases had significantly higher levels of CXCL16 –  
256 effect that is statistically significant.



257  
258  
259  
260  
261  
262  
263  
264

265 **Supplemental Figure 2** Scatter plot between CXCL16 and IFN $\gamma$  and TNF $\alpha$  (baseline samples collected  
266 from COVID-19 hospitalized patients with severity determined with WHO scale)



267

268

269

270

271

272

273

274

275

276

277

278

279

280


281

282

283

284

285 **Supplemental Figure 3** Correlation between age and CXCL16 plasma levels (collected at baseline from  
286 COVID-19 hospitalized patients)




287  
288  
289  
290  
291  
292  
293  
294  
295  
296

297 **Supplemental Figure 4** Association between genotype status and CXCL16 plasma levels (collected at  
298 baseline form COVID-19 hospitalized patients)

299

### FYCO1 3UTR rs60431156 vs CXCL16



300

301

302

303

304

305

306

307

308 Table 1

<b>Characteristic</b>	<b>Total (N=141)</b>
<b>Age (years)</b>	<b>64 (54 - 72)</b>
<b>Sex, n (%)</b>	
Male	91 (64.5)
Female	50 (35.5)
<b>Race, n (%)</b>	
Asian	2 (1.4)
Black or African American	35 (24.8)
Native Hawaiian or Other Pacific Islander	1 (0.7)
White	73 (51.8)
Other	30 (21.3)
<b>Any Comorbidities, n (%)</b>	<b>135 (95.7)</b>
Hypertension	80 (56.7)
Diabetes	56 (39.7)
Coronary Heart Disease	10 (7.1)
Asthma	16 (11.3)
<b>7 Point Ordinal Scale at Baseline, n (%)</b>	
2 - Hospitalized on mechanical ventilation or ECMO	8 (5.7)
3 - Hospitalized on non-invasive ventilation or high-flow oxygen supplement	69 (48.9)
4 - Hospitalized requiring supplemental oxygen	61 (43.3)
5 - Hospitalized not requiring supplemental oxygen, requiring continued medical care	3 (2.1)

309

310

311

312

313

314

315

316

317

318

319

320

321

322 Table 2

---

<b>Characteristic</b>	<b>Total (N=141)</b>
<b>Time from Hospitalization to Starting Study Treatment, Days</b>	<b>4 (2 - 7)</b>
Early (<=10 Days from Hospitalization)	127 (90.1)
Late (>10 Days from Hospitalization)	14 (9.9)
<b>Highest Oxygen Therapy Support</b>	
Room Air	3 (2.1)
Nasal Cannula (NC)	46 (32.6)
Non Rebreather (NRB)	15 (10.6)
High Flow Nasal Cannula (HFNC)	52 (36.9)
CPAP Mask	7 (5.0)
BiPAP Mask	10 (7.1)
Mechanical Ventilation	8 (5.7)
<b>Concomitant Medications, n (%)*</b>	<b>39 (27.7)</b>
Azithromycin	19 (13.5)
Tocilizumab	4 (2.8)
Hydroxychloroquine	12 (8.5)
Steroids#	21 (14.9)

---